Showing 4131-4140 of 5623 results for "".
- Eyenovia Announces Planned Chief Executive Officer Transitionhttps://modernod.com/news/eyenovia-announces-planned-chief-executive-officer-transition/2480898/Eyenovia announced that Sean Ianchulev, MD, co-founder, chief medical officer, and chief executive officer, will step down as chief executive officer and transition to the role of non-executive Chairman of the Board. The definitive timeline for the transition will be determin
- NIH: Gene Therapy for Rare Eye Disease Safe But Lacks Efficacy in Early Trialhttps://modernod.com/news/nih-gene-therapy-for-rare-eye-disease-safe-but-lacks-efficacy-in-early-trial/2480896/A 28-patient phase 1 gene therapy clinical trial for the degenerative retinal disease Leber hereditary optic neuropathy (LHON) found no significant safety concerns; however, treatment failed to improve or slow vision loss, with even the highest dose. LHON affects the optic nerve, which carries vi
- NIH Study Confirms Benefit of Supplements for Slowing AMDhttps://modernod.com/news/nih-study-confirms-benefit-of-supplements-for-slowing-age-related-macular-degeneration-amd/2480894/The Age-Related Eye Disease Studies (AREDS and AREDS2) established that dietary supplements can slow progression of age-related macular degeneration (AMD), according to the Nationa
- The Vision Council Announces that Version 3.13 of the Data Communication Standard is Now Availablehttps://modernod.com/news/the-vision-council-announces-that-version-313-of-the-data-communication-standard-is-now-available/2480893/The Vision Council announced the publication of Version 3.13 of the Standard for Data Communications. The standard, which is used by manufacturers of optical lab equipment and producers of software used in optical labs, was developed by The Vision Council’s Lens Proce
- Novartis Receives FDA Approval of Beovu for the Treatment of Diabetic Macular Edemahttps://modernod.com/news/novartis-announces-fda-approval-of-beovu-for-the-treatment-of-diabetic-macular-edema/2480891/Novartis announced that the FDA has approved Beovu (brolucizumab-dbll) 6 mg for the treatment of diabetic macular edema (DME). Today’s approval represents the second FDA-approved indication for Beovu, which was first approved for the treatment of wet age-related macular degeneration in
- Apellis Submits New Drug Application to the FDA for Pegcetacoplan for Geographic Atrophyhttps://modernod.com/news/apellis-announces-submission-of-nda-to-the-fda-for-pegcetacoplan-for-geographic-atrophy/2480890/Apellis Pharmaceuticals announced that the company has submitted a new drug application (NDA) to the FDA for intravitreal pegcetacoplan, an investigational, targeted C3 therapy, for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD)
- Oertli Expands its Direct Distribution Networkhttps://modernod.com/news/oertli-expands-its-direct-distribution-network/2480889/Oertli Instrumente acquired the Swiss distributor Domedics AG and integrated the company as of June 1 into their global brand. Terms of the deal were not disclosed. In September 2021, Oertli Instrumente took over the majority of shares in Domedics, a Switzerland-base
- "Artificial Intelligence in Ophthalmology 2022" Conference is Being Held Onlinehttps://modernod.com/news/artificial-intelligence-in-ophthalmology-2022-conference-is-being-held-online/2480884/The "Artificial Intelligence in Ophthalmology 2022" conference is being held online on June 3, 2022. The conference will feature an overview of artificial intelligence (AI), machine learning (ML) and deep learning (
- AMA: Health Insurance Industry Continues to Falter on Prior Authorization Reformhttps://modernod.com/news/ama-health-insurance-industry-continues-to-falter-on-prior-authorization-reform/2480880/Despite mounting evidence that insurer-imposed authorizations for drugs and medical services can be a hazardous and burdensome administrative obstacle to patient-centered care, the health insurer industry continues to show apathetic or ineffectual follow-through on mutually accepted reforms, acco
- Aerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 COMET-2 Study of AR-15512 for the Treatment of Dry Eye Diseasehttps://modernod.com/news/aerie-pharmaceuticals-announces-first-participant-dosed-in-the-phase-3-comet-2-study-of-ar-15512-for-the-treatment-of-dry-eye-disease/2480879/Aerie Pharmaceuticals announced that the first participant has been dosed in the phase 3 registrational “COMET-2” study to evaluate AR-15512 ophthalmic solution as a treatment for the signs and symptoms of dry eye disease (DED). COMET-2 is the first of three trials in t